Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07012044

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Sponsor: National Cancer Institute (NCI)

Conditions Acute Myeloid Leukemia Post Cytotoxic Therapy Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Interventions Biospecimen Collection Bone Marrow Aspiration Bone Marrow Biopsy Decitabine Decitabine and Cedazuridine Filgrastim Imaging Procedure Lumbar Puncture

Updated 3 times since 2025 Last updated: Mar 12, 2026 Started: Oct 30, 2026 Primary completion: Jan 1, 2027 Completion: Jan 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Myeloid Leukemia Post Cytotoxic Therapy and Recurrent Acute Myeloid Leukemia and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Not Yet Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Not Yet Recruiting PHASE1
Jul 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.